NO20032625L - Indazolyl-substituerte pyrrolinforbindelser som kineaseinhibitorer - Google Patents

Indazolyl-substituerte pyrrolinforbindelser som kineaseinhibitorer

Info

Publication number
NO20032625L
NO20032625L NO20032625A NO20032625A NO20032625L NO 20032625 L NO20032625 L NO 20032625L NO 20032625 A NO20032625 A NO 20032625A NO 20032625 A NO20032625 A NO 20032625A NO 20032625 L NO20032625 L NO 20032625L
Authority
NO
Norway
Prior art keywords
indazolyl
kinase inhibitors
kinase
substituted pyrroline
compounds
Prior art date
Application number
NO20032625A
Other languages
English (en)
Norwegian (no)
Other versions
NO20032625D0 (no
Inventor
Han-Cheng Zhang
Bruce E Maryanoff
Bruce Conway
Kimberly White
Hong Ye
Leonard R Hecker
David F Mccomsey
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Publication of NO20032625D0 publication Critical patent/NO20032625D0/no
Publication of NO20032625L publication Critical patent/NO20032625L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
NO20032625A 2000-12-08 2003-06-10 Indazolyl-substituerte pyrrolinforbindelser som kineaseinhibitorer NO20032625L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25416600P 2000-12-08 2000-12-08
PCT/US2001/047689 WO2002046183A2 (en) 2000-12-08 2001-12-06 Indazolyl-substituted pyrroline compounds as kinase inhibitors

Publications (2)

Publication Number Publication Date
NO20032625D0 NO20032625D0 (no) 2003-06-10
NO20032625L true NO20032625L (no) 2003-08-05

Family

ID=22963185

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20032625A NO20032625L (no) 2000-12-08 2003-06-10 Indazolyl-substituerte pyrrolinforbindelser som kineaseinhibitorer

Country Status (25)

Country Link
US (4) US6849643B2 (de)
EP (1) EP1362047B1 (de)
JP (1) JP2004515499A (de)
KR (1) KR20040016828A (de)
CN (1) CN1230434C (de)
AT (1) ATE326464T1 (de)
AU (1) AU2002230727A1 (de)
BR (1) BR0116468A (de)
CA (1) CA2431166A1 (de)
CY (1) CY1106125T1 (de)
CZ (1) CZ20031594A3 (de)
DE (1) DE60119790T2 (de)
DK (1) DK1362047T3 (de)
ES (1) ES2263681T3 (de)
HU (1) HUP0303855A3 (de)
IL (1) IL156339A0 (de)
MX (1) MXPA03005140A (de)
NO (1) NO20032625L (de)
NZ (1) NZ526356A (de)
PL (1) PL362576A1 (de)
PT (1) PT1362047E (de)
RU (1) RU2003117078A (de)
WO (1) WO2002046183A2 (de)
YU (1) YU46603A (de)
ZA (1) ZA200305239B (de)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0116468A (pt) * 2000-12-08 2004-06-29 Ortho Mcneil Pharm Inc Compostos de pirrolina substituìda por indazolila como inibidores de cinase
KR20050040832A (ko) * 2001-10-29 2005-05-03 넥타르 테라퓨틱스 에이엘, 코포레이션 단백질 키나아제 ｃ 억제제의 중합체 공액
ES2276048T3 (es) 2002-03-05 2007-06-16 Eli Lilly And Company Derivados de purina como inhibidores de cinasa.
ATE368657T1 (de) 2002-03-08 2007-08-15 Lilly Co Eli Pyrrol-2,5-dion derivate und deren verwendung als gsk-3 inhibitoren
CA2485527A1 (en) * 2002-05-08 2003-11-20 Janssen Pharmaceutica N.V. Substituted pyrroline kinase inhibitors
ES2312785T3 (es) * 2002-06-05 2009-03-01 Janssen Pharmaceutica Nv Pirrolinas sustituidas utiles como inhibidores de quinasa.
JP2006521386A (ja) * 2003-03-27 2006-09-21 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ キナーゼ阻害剤である置換ピロリン
US7439363B2 (en) * 2003-06-13 2008-10-21 Janssen Parmaceutica N.V. Substituted indazoly(indoly)maleimide derivatives as kinase inhibitors
JP4499721B2 (ja) * 2003-06-30 2010-07-07 ヒフ バイオ，インク． 化合物、組成物および方法
JP2007505628A (ja) * 2003-09-19 2007-03-15 チルドレンズ ホスピタル メディカル センター 心収縮能及び心不全傾向の調節
WO2005030130A2 (en) * 2003-09-23 2005-04-07 Merck & Co., Inc. Isoquinoline potassium channel inhibitors
MX2007006190A (es) * 2004-11-23 2008-01-22 Internat Bio Therapeutic Res Inc Metodo de suministro de iones metalicos terapeuticos, aleaciones y sales.
US8017395B2 (en) 2004-12-17 2011-09-13 Lifescan, Inc. Seeding cells on porous supports
SE0500058D0 (sv) * 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 5
MX2007008370A (es) 2005-01-10 2007-08-21 Astrazeneca Ab Derivados de 1,1-dioxidos de isotiazol-3 (2h) -ona como moduladores del receptor del higado x.
SE0500055D0 (sv) 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 3
WO2006102079A1 (en) * 2005-03-17 2006-09-28 Novartis Ag N- [3- (1-amin0-5, 6, 7, 8-tetrahydro-2 , 4, 4b-triazafluoren-9-yl)-phenyl] benzamides as tyrosine/threonine kinase inhibitors, in particular b-raf kinase
JP2009500297A (ja) 2005-06-08 2009-01-08 セントカー・インコーポレーテツド 眼の変性についての細胞療法
WO2007008514A2 (en) * 2005-07-07 2007-01-18 Georgetown University Inhibitors of glycogen synthase kinase 3
WO2007041195A2 (en) * 2005-09-29 2007-04-12 Janssen Pharmaceutica N.V. Macroheterocylic compounds as kinase inhibitors
US8741643B2 (en) 2006-04-28 2014-06-03 Lifescan, Inc. Differentiation of pluripotent stem cells to definitive endoderm lineage
US7741290B2 (en) 2006-06-01 2010-06-22 The Board of Trustee of The Leland Stanford Juinior University Method of preventing progression of hypertension-induced heart failure with PKC peptides
CA2673368C (en) 2006-12-19 2014-10-28 The Board Of Trustees Of The University Of Illinois 3-benzofuranyl-4-indolyl maleimides as potent gsk3 inhibitors for neurogenerative disorders
EP2134683A2 (de) * 2007-02-12 2009-12-23 Intermune, Inc. Neue replikationshemmer des hepatitis-c-virus
US9080145B2 (en) 2007-07-01 2015-07-14 Lifescan Corporation Single pluripotent stem cell culture
RU2473685C2 (ru) 2007-07-31 2013-01-27 Лайфскен, Инк. Дифференцировка человеческих эмбриональных стволовых клеток
CN107574142B (zh) 2007-11-27 2021-07-06 生命扫描有限公司 人胚胎干细胞的分化
BRPI0908033A2 (pt) 2008-02-21 2015-08-04 Centocor Ortho Biotech Inc Método placas de superfície modificada e composições para adesão, cultura e desprendimento de célula
US8623648B2 (en) 2008-04-24 2014-01-07 Janssen Biotech, Inc. Treatment of pluripotent cells
CA2729121C (en) 2008-06-30 2019-04-09 Centocor Ortho Biotech Inc. Differentiation of pluripotent stem cells
EP2346988B1 (de) 2008-10-31 2017-05-31 Janssen Biotech, Inc. Differenzierung menschlicher embryonaler stammzellen in die pankreatisch-endokrine linie
JP2012507289A (ja) 2008-10-31 2012-03-29 ヤンセン バイオテツク，インコーポレーテツド ヒト胚性幹細胞の膵内分泌系への分化
MX2011005288A (es) 2008-11-20 2011-06-01 Centocor Ortho Biotech Inc Celulas madre pluripotentes en microportadores.
CA2744227C (en) 2008-11-20 2018-10-02 Centocor Ortho Biotech Inc. Methods and compositions for cell attachment and cultivation on planar substrates
EP2456862A4 (de) 2009-07-20 2013-02-27 Janssen Biotech Inc Differenzierung menschlicher embryonischer stammzellen
RU2540016C2 (ru) 2009-07-20 2015-01-27 Янссен Байотек, Инк. Дифференцировка эмбриональных стволовых клеток человека
EP2456858B1 (de) 2009-07-20 2018-08-29 Janssen Biotech, Inc. Differenzierung menschlicher embryonischer stammzellen
DK2516625T3 (da) 2009-12-23 2024-09-09 Janssen Biotech Inc Differentiering af humane embryonale stamceller
RU2664864C1 (ru) 2009-12-23 2018-08-23 Янссен Байотек, Инк. Способы увеличения экспрессии ngn3 и nkx6.1 в эндокринных клетках поджелудочной железы
AU2011223900A1 (en) 2010-03-01 2012-09-13 Janssen Biotech, Inc. Methods for purifying cells derived from pluripotent stem cells
JP2013526542A (ja) 2010-05-12 2013-06-24 アッヴィ・インコーポレイテッド キナーゼのインダゾール阻害薬
AU2011250912A1 (en) 2010-05-12 2012-11-22 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
KR101836850B1 (ko) 2010-08-31 2018-03-09 얀센 바이오테크 인코포레이티드 인간 배아 줄기 세포의 분화
CN103221536B (zh) 2010-08-31 2016-08-31 詹森生物科技公司 人胚胎干细胞的分化
WO2012030540A2 (en) 2010-08-31 2012-03-08 Janssen Biotech, Inc. Differentiation of pluripotent stem cells
RU2705001C2 (ru) 2011-12-22 2019-11-01 Янссен Байотек, Инк. Дифференцировка эмбриональных стволовых клеток человека в одногормональные инсулинположительные клетки
MX354775B (es) 2012-03-07 2018-03-20 Janssen Biotech Inc Medios definidos para la expansion y el mantenimiento de celulas madre pluripotentes.
CN104334719B (zh) 2012-06-08 2018-02-13 詹森生物科技公司 人胚胎干细胞向胰腺内分泌细胞的分化
US9724331B2 (en) 2012-12-10 2017-08-08 Centogene Ag Use of maleimide derivatives for preventing and treating leukemia
DK2938722T3 (da) 2012-12-31 2022-02-14 Janssen Biotech Inc Suspension og klyngedannelse af humane pluripotente celler til differentiering til endokrine pankreasceller
US10370644B2 (en) 2012-12-31 2019-08-06 Janssen Biotech, Inc. Method for making human pluripotent suspension cultures and cells derived therefrom
MX2015008578A (es) 2012-12-31 2015-09-07 Janssen Biotech Inc Diferenciacion de celulas madre embrionarias humanas en celulas endocrinas pancreaticas mediante el uso de relugadores de hb9.
KR102084561B1 (ko) 2012-12-31 2020-03-04 얀센 바이오테크 인코포레이티드 췌장 내분비 세포로의 분화를 위한 공기-액체 계면에서의 인간 배아 줄기세포의 배양
SG11201609473XA (en) 2014-05-16 2016-12-29 Janssen Biotech Inc Use of small molecules to enhance mafa expression in pancreatic endocrine cells
GB201509885D0 (en) * 2015-06-08 2015-07-22 Ucb Biopharma Sprl Therapeutic agents
WO2017180361A1 (en) 2016-04-14 2017-10-19 Janssen Biotech, Inc. Differentiation of pluripotent stem cells to intestinal midgut endoderm cells
US10383881B2 (en) 2016-12-30 2019-08-20 Frequency Therapeutics, Inc. 1,5-dihydro-2H-pyrrol-2-one compounds and methods of using same
AU2017386417B2 (en) 2016-12-30 2022-07-14 Frequency Therapeutics, Inc. 1H-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells
LT3860998T (lt) 2018-10-05 2024-06-25 Annapurna Bio Inc. Junginiai ir kompozicijos, skirti gydyti būkles, susijusias su apj receptoriaus aktyvumu
WO2020163812A1 (en) 2019-02-08 2020-08-13 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders
PT4097099T (pt) 2020-02-07 2024-07-19 Gasherbrum Bio Inc Agonistas heterocíclicos de glp-1
WO2022052958A1 (en) 2020-09-10 2022-03-17 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
KR20250168210A (ko) 2023-02-16 2025-12-02 가셔브룸 바이오, 인크. 헤테로시클릭 glp-1 효능제

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ280738B6 (cs) 1988-02-10 1996-04-17 F. Hoffmann - La Roche And Co., Aktiengesellschaft Substituované pyrroly, jejich použití pro výrobu léčiv a léčiva na jejich bázi
GB8904161D0 (en) 1989-02-23 1989-04-05 Hoffmann La Roche Substituted pyrroles
MC2096A1 (fr) 1989-02-23 1991-02-15 Hoffmann La Roche Pyrroles substitues
DE4005970A1 (de) 1990-02-26 1991-08-29 Boehringer Mannheim Gmbh Neue trisubstituierte maleinimide, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
DE4005969A1 (de) 1990-02-26 1991-08-29 Boehringer Mannheim Gmbh Neue trisubstituierte pyrrole, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
US5624949A (en) 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
EP1449529B1 (de) 1993-12-23 2010-01-27 Eli Lilly And Company Proteinkinase C Inhibitoren
SE9603283D0 (sv) 1996-09-10 1996-09-10 Astra Ab New compounds
AU2548699A (en) 1998-02-23 1999-09-06 Rei Asakai Cell death inhibitors
HUP0103381A3 (en) 1998-07-30 2002-07-29 Japan Tobacco Inc Disubstituted maleimide compounds and medicinal utilization thereof and the pharmaceutical compositions containing the same
JP2002527419A (ja) 1998-10-08 2002-08-27 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー Ｇｓｋ−３阻害物質としてのピロール−２，５−ジオン類
BR0116468A (pt) * 2000-12-08 2004-06-29 Ortho Mcneil Pharm Inc Compostos de pirrolina substituìda por indazolila como inibidores de cinase
CA2485527A1 (en) 2002-05-08 2003-11-20 Janssen Pharmaceutica N.V. Substituted pyrroline kinase inhibitors
JP2005531609A (ja) 2002-06-05 2005-10-20 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ キナーゼ阻害剤としてのシスインドリル−マレイミド誘導体
ES2312785T3 (es) 2002-06-05 2009-03-01 Janssen Pharmaceutica Nv Pirrolinas sustituidas utiles como inhibidores de quinasa.
JP2006521386A (ja) 2003-03-27 2006-09-21 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ キナーゼ阻害剤である置換ピロリン
US7439363B2 (en) * 2003-06-13 2008-10-21 Janssen Parmaceutica N.V. Substituted indazoly(indoly)maleimide derivatives as kinase inhibitors

Also Published As

Publication number Publication date
AU2002230727A1 (en) 2002-06-18
ZA200305239B (en) 2004-10-07
PT1362047E (pt) 2006-09-29
US20030055097A1 (en) 2003-03-20
US20050004202A1 (en) 2005-01-06
DE60119790D1 (de) 2006-06-22
DK1362047T3 (da) 2006-09-04
BR0116468A (pt) 2004-06-29
CN1230434C (zh) 2005-12-07
HUP0303855A3 (en) 2005-04-28
US20040259928A1 (en) 2004-12-23
RU2003117078A (ru) 2004-12-10
US7329657B2 (en) 2008-02-12
IL156339A0 (en) 2004-01-04
CN1489586A (zh) 2004-04-14
DE60119790T2 (de) 2007-01-25
CY1106125T1 (el) 2011-06-08
US20080096949A1 (en) 2008-04-24
WO2002046183A3 (en) 2002-09-06
CA2431166A1 (en) 2002-06-13
EP1362047B1 (de) 2006-05-17
CZ20031594A3 (cs) 2004-06-16
HK1057370A1 (en) 2004-04-02
NZ526356A (en) 2005-02-25
NO20032625D0 (no) 2003-06-10
WO2002046183A2 (en) 2002-06-13
PL362576A1 (en) 2004-11-02
US7304060B2 (en) 2007-12-04
JP2004515499A (ja) 2004-05-27
MXPA03005140A (es) 2004-10-15
US6849643B2 (en) 2005-02-01
ES2263681T3 (es) 2006-12-16
EP1362047A2 (de) 2003-11-19
KR20040016828A (ko) 2004-02-25
US7855203B2 (en) 2010-12-21
ATE326464T1 (de) 2006-06-15
HUP0303855A2 (hu) 2004-03-01
YU46603A (sh) 2006-05-25

Similar Documents

Publication Publication Date Title
DK1362047T3 (da) Indazolylsubstituerede pyrrolinforbindelser som kinaseinhibitorer
DE60323749D1 (de) Substituierte pyrroline als kinase inhibitoren
DE60319364D1 (de) Substituierte pyrroline als kinase inhibitoren
AU2737102A (en) Macroheterocylic compounds useful as kinase inhibitors
BG106585A (en) Kinase inhibitors as therapeutic agents
YU84603A (sh) Novi inhibitori tirozin kinaze
EA200300906A1 (ru) Новые спиротрициклические производные и их применение в качестве ингибиторов фосфодиэстеразы-7
MXPA03011907A (es) Fluoropirrolidinas como inhibidores de dipeptidil peptidasa.
MXPA02005844A (es) Inhibidores de cinasas de proteina.
ECSP056222A (es) Derivados de indazolil(indolil)maleimida sustituidoscomo inhibidores de cinasa
EA200401157A1 (ru) N-аминоацетилпирролидин-2-карбонитрилы и их применение в качестве ингибиторов ddp-iv
AU3741801A (en) Substituted beta-carbolines with ikb-kinase inhibiting activity
AU5584901A (en) Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease
BRPI0412894A (pt) tienopiridina e furopiridina inibidores de quinases
EP1534695A4 (de) Tyrosinkinaseinhibitoren
WO2004030620A3 (en) Novel tyrosine kinase inhibitors
BR0209149A (pt) Ftalazinonas
PL371127A1 (en) 6-aminomorphinane derivatives, method for the production and use thereof
ATE411287T1 (de) Neue metallproteinaseinhibitoren
DE602004005881D1 (de) Substituierte pyrazinonverbindungen zur behandlung von entzündungen
DE60329326D1 (de) Tace inhibitoren
DE60121587D1 (de) Zyklische gmp-spezifische phosphodiesteraseinhibitoren
EP1496907A4 (de) Tyrosinkinase-hemmer
EP1496898A4 (de) Tyrosinkinase-hemmer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application